Printer-friendly versionPrinter-friendly version

List of VHPB publications online available

Many European countries 'flying blind' in their efforts to eliminate viral hepatitis.
Lazarus JV, Safreed-Harmon K, Colombo M, Reic T, Schatz E, Van Damme P; ACHIEVE Coalition.
Nat Rev Gastroenterol Hepatol. 2017 Jul 26;14(8):445-446. doi: 10.1038/nrgastro.2017.98.
Single-Dose Hepatitis A Immunization: 7.5-Year Observational Pilot Study in Nicaraguan Children to Assess Protective Effectiveness and Humoral Immune Memory Response.
Mayorga O, Bühler S, Jaeger VK, Bally S, Hatz C, Frösner G, Protzer U, Van Damme P, Egger M, Herzog C.
J Infect Dis. 2016 Nov 15;214(10):1498-1506
Innovative sources for funding of viral hepatitis prevention and treatment in low- and middle-income countries: a roundtable meeting report.
David FitzSimons, Greet Hendrickx, Johannes Hallauer, Heidi Larson, Daniel Lavanchy, Ina Lodewyckx,Daniel Shouval, John Ward and Pierre Van Damme.
Hepatology, Medicine and Policy; 2016, 1:16. DOI 10.1186/s41124-016-0022-8
Editorial on "What is a potentially damaging vaccination delay in children younger than 2 years?"
Kane MA, Roudot-Thoraval F, Guerin N, Papaevangelou V, Van Damme P; Viral Hepatitis Prevention Board.
Hum Vaccin Immunother. 2016 Aug 2;12(8):2053-2056.
A hepatitis-free future: strategy first, then pricing.
Heidi Larson, Pierre Van Damme & David FitzSimons
Lancet Infect Dis & 2016, 16(4):399-400. doi: 10.1016/S1473-3099(16)00126-2.
Editorial on “What is a potentially damaging vaccination delay in children younger than 2 years?”
Mark A. Kane, Francois Roudot-Thoraval, Nicole Guerin, Vassiliki Papaevangelou, Pierre Van Damme & on behalf of the Viral Hepatitis Prevention Board
Human Vaccines & Immunotherapeutics 2016, DOI:10.1080/21645515.2016.1177689
Long-term Protection After Hepatitis B Vaccine
van Damme P
J Infect Dis. 2016, doi: 10.1093/infdis/jiv750
Prevalence of HBV and HCV among outpatients in the plovdiv region of Bulgaria,2010-2011
Kevorkyan A1, Teoharov P, Lernout T, Petrova N, Raycheva R, Ivanov I, van Damme P, Kojouharova M.
J Med Virol 2015,87: 401-406
A cohesive European policy for hepatitis B vaccination, are we there yet?
Lernout T, Hendrickx G, Vorsters A, Mosina L, Emiroglu N, Van Damme P.
Clin Microbiol Infect 2014,20 Suppl 5: 19-24
Viral Hepatitis Prevention B. Reduced prevalence of HBsAg variants following a successful immunization program in China.
Jilg W, Norder H, Kane M, Van Damme P, Vorsters A.
J Virol 2014, 88: 4605-4606
Incentives and barriers regarding immunization against influenza and hepatitis of health care workers.
Meeting report Barcelona
FitzSimons D, Hendrickx G, Lernout T, Badur S, Vorsters A, Van Damme P.
Vaccine 2014, 32: 4849-4854
Burden and prevention of viral hepatitis in the Arctic region, Copenhagen, Denmark, 22 23 March 2012
Meeting report
David FitzSimons, Brian McMahon, Greet Hendrickx, Alex Vorsters, Pierre Van Damme
Int J Circumpolar Health 2013, 72: 21163 99 Kb
Should Europe have a universal hepatitis B vaccination programme?
Head to head
Pierre Van Damme, Elke Leuridan, Greet Hendrickx, Alex Vorsters, Heidi Theeten
BMJ 2013, 347: f4057 163 Kb
Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? Milan, Italy, 17-18 November 2011.
Meeting report Milan
FitzSimons D, Hendrickx G, Vorsters A, Van Damme P
Vaccine 2013, 31: 584-590
Advances in hepatitis immunization (A, B, E): public health policy and novel vaccine delivery.
Hendrickx G, Vorsters A, Van Damme P. A.
Curr Opin Infect Dis 2012, 25: 578-583
Identification and management of persons with chronic viral hepatitis in Europe
Meeting report Budapest
David FitzSimons, Greet Hendrickx, Alex Vorsters, Pierre Van Damme
European Gastroenterology & Hepatology Review, vol 8, Iss 1, spring 2012 5,6 Mb
Burden and prevention of viral hepatitis in Bulgaria.
Meeting report Bulgaria
Fitzsimons D, Kojouharova M, Hallauer J, Hendrickx G, Vorsters A, Van Damme P.
Vaccine 2011, 29: 8471-8476 5,6 Mb
Hepatitis A and E: Update on Prevention and Epidemiology
Meeting report
David FitzSimons, Greet Hendrickx, Alex Vorsters, Pierre Van Damme
Vaccine 2009, 28: 583 - 588 121 Kb
The clock is running.
Vorsters A, Van Herck K, Van Damme P.
Vaccine 2009, 27: 2905-2906 121 Kb
Prevention of viral hepatitis (B and C) reassessed.
Van Herck K, Vorsters A, Van Damme P.
Best Pract Res Clin Gastroenterol 2008, 22: 1009-1029 121 Kb
Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology.
Meeting report Hepatitis A, Miami 2007
Hendrickx G, Van Herck K, Vorsters A, Wiersma S, Shapiro C, Andrus JK, et al.
J Viral Hepat 2008,15 (Suppl 2): 1-15 110 Kb
Prevention and control of viral hepatitis: the role and impact of patient and advocacy groups in and outside Europe.
Meeting report Lucca, Italy 2008
FitzSimons DW
Vaccine 2008, 26: 5669-5674 125 Kb
Prevention and control of viral hepatitis through adolescent health programmes in Europe
Meeting report Ljubljana, Slovenia 2007
David FitzSimons, Alex Vorsters, Karel Hoppenbrouwers, Pierre Van Damme
Vaccine 2007, 25: 8651-865 110 Kb
Hepatitis B virus, hepatitis C virus and other blood-borne infections in healthcare workers: guidelines for prevention and management in industrialised countries.
Meeting report Rome, Italy 2005
FitzSimons D, Francois G, De Carli G, Shouval D, Pruss-Ustun A, Puro V, Williams I, Lavanchy D, De Schryver A, Kopka A, Ncube F, Ippolito G, Van Damme P.
143 Kb
Measurement and reporting of burden of disease for hepatitis A: results of the EUROHEP.NET feasibility survey.
Report Eurohep.Net project
Bonanni P, Boccalini S, Bechini A.
Eur J Public Health 2007, 17:69-74 90 Kb
Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants.
Report Sevillia, Spain 2004
Fitzsimons D, Francois G, Hall A, McMahon B, Meheus A, Zanetti A, Duval B, Jilg W, Bocher WO, Lu SN, Akarca U, Lavanchy D, Goldstein S, Banatvala J, Damme PV.
Vaccine 2005, 23: 4158-4166 112 Kb
Prevention of viral hepatitis in the Nordic countries and Germany
Meeting report Berlin, Germany 2003
Fitzsimons D, Francois G, Alpers K, Radun D, Hallauer J, Jilg W, Gerlich W, Rombo L, Blystad H, Nokleby H, van Damme P.
Scand J Infect Dis 2005, 37: 549-560
Prevention of viral hepatitis in Italy.
Report Italy 2004
FitzSimons, D., Francois, G., Bonanni, P., Mele, A., Zanetti, A., Stroffolini, T., Crovari, P. and Van Damme, P.
Vaccine 2004, 22: 4092-4096 66 Kb
Combined hepatitis B vaccines.
Report Malta meeting 2001
FitzSimons D, Francois G, Emiroglu N, Van Damme P.
Vaccine 2003, 21: 1310-1316 64 Kb
Hepatitis B vaccination in Britain: time to change ?
Editorial
Jangu Banatvala, Pierre Van Damme, Nedret Emiroglu
BMJ 2006, 332: 804 46 Kb
Strengthening immunisation systems and introduction of hepatitis B vaccine in CEE and NIS 
Meeting report
Alexandra Levitt, Alex Vorsters, Nedret Emiroglu, Susan Goldstein, Tore Godal, Mark Kane, Dragoslav Popovic, Steven Wiersma, Pierre Van Damme
May 2004 1,652 Kb
Strengthening immunisation systems and introduction of hepatitis B vaccine in CEE and NIS
Meeting report
David FitzSimons, Pierre Van Damme, Nedret Emiroglu, Tore Godal, Mark Kane, Alexander Malyavin, Harold Margolis, André Meheus
Vaccine 2002, 20(11-12): 1475-9 626 Kb
A Technical Consultation on the Safety of hepatitis B Vaccines
Meeting report
Andy Hall, Pierre Van Damme
Sep 1998 218 Kb (.doc)
Prevention and control of hepatitis B in Central and Eastern Europe and the Newly Independent States, Siofok, Hungary, 6-9 October 1996
Meeting report
David Fitzsimons, Pierre Van Damme
Oct 1996 568 Kb (.doc)

List of other VHPB documents available in hard copy

Vaccine safety controversies and the future of vaccination programs
Meeting report
Guido François, Philippe Duclos, Harold Margolis, Daniel Lavanchy, Claire-Anne Siegrist, André Meheus, Paul-Henri Lambert, Nedret Emiroglu, Selim Badur, Pierre Van Damme
Pediatr Infect Dis J. 2005, 24(11): 953-961 Vhpb other publications - mail order
Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants
Meeting report
David FitzSimons, Guido François, Andy Hall, Brian McMahon, André Meheus, Alessandro Zanetti, Bernard Duval, Wolfgang Jilg, Wulf Böcher, Sheng-Nan Lu, Ulus Akarca, Daniel Lavanchy, Susan Goldstein, Jangu Banatvala, Pierre Van Damme
Vaccine 2005, 23: 4158-4166 Vhpb other publications - mail order
Prevention of viral hepatitis in the Nordic Countries and Germany
Meeting report
David FitzSimons, Guido François, Katharina Alpers, Doris Radun, Johannes Hallauer, Wolfgang Jilg, Wolfram Gerlich, Lars Rombo,, Hans Blystad, Hanne Nokleby, Pierre Van Damme
Scandinavian Journal of Infectious Diseases 2005, 37 (8): 549-561 Vhpb other publications - mail order
Prevention of hepatitis C virus infection
Meeting report
Michael Kew, Guido François, Daniel Lavanchy, Harold Margolis, Pierre Van Damme, Peter Grob, Johannes Hallauer, Daniel Shouval, Geert Leroux-Roels, André Meheus
Journal of Viral Hepatitis 2004, 11: 198-205 Vhpb other publications - mail order
Prevention of viral hepatitis in Italy
Meeting report
David FitzSimons, Guido François, Paolo Bonanni, Alfonso Mele, Alessandro Zanetti, Tommaso Stroffolini, Pietro Crovari, Pierre Van Damme
Vaccine 2004, 22: 4092-4096 Vhpb other publications - mail order
Combined hepatitis B vaccines
Meeting report
David Fitzsimons, Guido François, Nedret Emiroglu, Pierre Van Damme
Vaccine 2003, 21: 1310-1316 Vhpb other publications - mail order
Economic evalutation of vaccination programmes; a consensus statement focusing on viral hepatitis
Review
Philippe Beutels, W. John Edmunds, Fernando Antonanzas, Marc Péchevis, David Evans, Rachel Feilden, A. Mark Fendrick, Gary M. Ginsberg, Henry A. Glick, Eric Mast, G. Ardine De Wit, Eddy Van Doorslaer, Ben A. van Hout
Pharmacoeconomics 2002: 20 (1): 1-7 Vhpb other publications - mail order
Hepatitis B vaccination: how to reach risk groups
Meeting report
Guido François, Johannes Hallauer, Pierre Van Damme
Vaccine 2002, 21: 1-4 Vhpb other publications - mail order
Strengthening immunisation systems and introduction of hepatitis B vaccine in CEE and NIS
Meeting report
David FitzSimons, Pierre Van Damme, Nedret Emiroglu, Tore Godal, Mark Kane, Alexander Malyavin, Harold Margolis, André Meheus
Vaccine 2002, 20: 1475-1479 Vhpb other publications - mail order
Behavioural Issues in hepatitis B Vaccination
Meeting report
Stephen Bartlett, Pierre Van Damme
Mar 2000   Vhpb other publications - mail order
Multiple Sclerosis and hepatitis B Vaccine?
Meeting report
Andy Hall, Mark Kane, André Meheus, Colette Roure
Vaccine 1999, 17 (20-21): 2473-2475 Vhpb other publications - mail order
Hepatitis B Vaccine and Central Nervous System Demyelinating Diseases 
Meeting report
Neal Halsey, Philippe Duclos, Pierre Van Damme, Harold Margolis
Pediatr. Infect. Dis. J. 1999, 18: 23-24 Vhpb other publications - mail order
Control of hepatitis B in Europe: where are we in 1997? 
Meeting report
Mark Kane, André Meheus, Pierre Van Damme
Vaccine, 1998, 16 (Suppl.): S1-S110 Vhpb other publications - mail order
Integration of hepatitis B vaccination into national immunisation programmes
Article
Pierre Van Damme, Mark Kane, André Meheus
BMJ 1997, 314: 1033-1037 Vhpb other publications - mail order
Prevention and Control of hepatitis B in Central and Eastern Europe and the Newly Independent States
Meeting report
David Fitzsimons, Pierre Van Damme
Vaccine 1997, 15 (15): 1595-1597 Vhpb other publications - mail order
Prevention and Control of hepatitis B in the Community 
Blue book, Communicable Diseases Series
P Grosheide, Pierre Van Damme
Jan 1996 Vhpb other publications - mail order
Proceedings of the International Congress on action towards control of hepatitis B as a community health risk
Meeting report
Johannes Hallauer, Wolfgang Jilg, Mark Kane, Pierre Van Damme
Vaccine 1995, 13 (Suppl. 1): S1-S116 Vhpb other publications - mail order
Hepatitis B as an occupational Hazard
Yellow book
European Occupational Health
  Vhpb other publications - mail order